NovaBridge Biosciences (NBP) - Total Liabilities
Based on the latest financial reports, NovaBridge Biosciences (NBP) has total liabilities worth $131.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NBP long-term investments to assets to see how much of total assets are deployed in long-term investments.
NovaBridge Biosciences - Total Liabilities Trend (2017–2024)
This chart illustrates how NovaBridge Biosciences's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of NovaBridge Biosciences.
NovaBridge Biosciences Competitors by Total Liabilities
The table below lists competitors of NovaBridge Biosciences ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
USA | $637.85 Million |
|
Topco Technologies
TWO:3388
|
Taiwan | NT$2.71 Billion |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM247.86 Million |
|
Southern Cross Media Group Ltd
AU:SXL
|
Australia | AU$1.42 Billion |
|
Tatung System Technologies
TWO:8099
|
Taiwan | NT$1.92 Billion |
|
Lindsay Australia Ltd
AU:LAU
|
Australia | AU$565.43 Million |
|
Hoegh LNG Partners LP
OL:HLNG
|
Norway | Nkr1.69 Billion |
|
Vietnam Container Shipping JSC
VN:VSC
|
Vietnam | ₫3.70 Trillion |
Liability Composition Analysis (2017–2024)
This chart breaks down NovaBridge Biosciences's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of NovaBridge Biosciences to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBridge Biosciences's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBridge Biosciences (2017–2024)
The table below shows the annual total liabilities of NovaBridge Biosciences from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.52 Million | -98.71% |
| 2023-12-31 | $894.81 Million | -16.01% |
| 2022-12-31 | $1.07 Billion | +2.28% |
| 2021-12-31 | $1.04 Billion | +47.41% |
| 2020-12-31 | $706.65 Million | -81.27% |
| 2019-12-31 | $3.77 Billion | +13.25% |
| 2018-12-31 | $3.33 Billion | +151.37% |
| 2017-12-31 | $1.33 Billion | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more